{"entity": "researcher", "timestamp": "2026-08-20T21:35:47.947Z", "family": "Salazar-Onfray", "given": "Flavio", "initials": "F", "orcid": "0000-0002-1848-5697", "affiliations": ["Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile.", "Millennium Institute on Immunology and Immunotherapy, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile.", "Science for Life Laboratory, Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden.", "Division of Infectious Diseases, Karolinska University Hospital, 17176 Stockholm, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/9d4f0919a9b444a1a690c9fb6cb9c25f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/9d4f0919a9b444a1a690c9fb6cb9c25f"}}, "publications": [{"entity": "publication", "iuid": "a71c46f25a9c401b977281217cb18601", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a71c46f25a9c401b977281217cb18601.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a71c46f25a9c401b977281217cb18601"}}, "title": "Long-Term Survival and Immune Response Dynamics in Melanoma Patients Undergoing TAPCells-Based Vaccination Therapy.", "authors": [{"family": "Tittarelli", "given": "Andr\u00e9s", "initials": "A", "orcid": "0000-0003-4129-9734", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4b33ae07f33248c2b87955e83d5fc6de.json"}}, {"family": "Pereda", "given": "Cristian", "initials": "C", "orcid": "0009-0000-1033-0247", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/aab236d1354243cc942b474809e714ec.json"}}, {"family": "Gleisner", "given": "Mar\u00eda A", "initials": "MA", "orcid": "0000-0002-4172-9709", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa028fc3b7b54583805e12ba55ef11da.json"}}, {"family": "L\u00f3pez", "given": "Mercedes N", "initials": "MN"}, {"family": "Flores", "given": "Iv\u00e1n", "initials": "I"}, {"family": "Tempio", "given": "Fabi\u00e1n", "initials": "F"}, {"family": "Lladser", "given": "Alvaro", "initials": "A", "orcid": "0000-0002-5576-1478", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/67fcde9ec88d497e91d5e64a2d785549.json"}}, {"family": "Achour", "given": "Adnane", "initials": "A", "orcid": "0000-0003-0432-710X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/65fba324156a4fcbafbe636e642587a9.json"}}, {"family": "Gonz\u00e1lez", "given": "Ferm\u00edn E", "initials": "FE", "orcid": "0000-0002-4212-1009", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/e9671a5793684845a35362cea70d03df.json"}}, {"family": "Dur\u00e1n-Aniotz", "given": "Claudia", "initials": "C", "orcid": "0000-0003-2503-8366", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0f0c51284b534d0ab63339baa9f07682.json"}}, {"family": "Miranda", "given": "Juan P", "initials": "JP"}, {"family": "Larrondo", "given": "Milton", "initials": "M"}, {"family": "Salazar-Onfray", "given": "Flavio", "initials": "F", "orcid": "0000-0002-1848-5697", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9d4f0919a9b444a1a690c9fb6cb9c25f.json"}}], "type": "journal article", "published": "2024-03-27", "journal": {"title": "Vaccines (Basel)", "issn": "2076-393X", "volume": "12", "issue": "4", "issn-l": null}, "abstract": "Cancer vaccines present a promising avenue for treating immune checkpoint blockers (ICBs)-refractory patients, fostering immune responses to modulate the tumor microenvironment. We revisit a phase I/II trial using Tumor Antigen-Presenting Cells (TAPCells) (NCT06152367), an autologous antigen-presenting cell vaccine loaded with heat-shocked allogeneic melanoma cell lysates. Initial findings showcased TAPCells inducing lysate-specific delayed-type hypersensitivity (DTH) reactions, correlating with prolonged survival. Here, we extend our analysis over 15 years, categorizing patients into short-term (<36 months) and long-term (\u226536 months) survivors, exploring novel associations between clinical outcomes and demographic, genetic, and immunologic parameters. Notably, DTHpos patients exhibit a 53.1% three-year survival compared to 16.1% in DTHneg patients. Extended remissions are observed in long-term survivors, particularly DTHpos/M1cneg patients. Younger age, stage III disease, and moderate immune events also benefit short-term survivors. Immunomarkers like increased C-type lectin domain family 2 member D on CD4+ T cells and elevated interleukin-17A were detected in long-term survivors. In contrast, toll-like receptor-4 D229G polymorphism and reduced CD32 on B cells are associated with reduced survival. TAPCells achieved stable long remissions in 35.2% of patients, especially M1cneg/DTHpos cases. Conclusions: Our study underscores the potential of vaccine-induced immune responses in melanoma, emphasizing the identification of emerging biological markers and clinical parameters for predicting long-term remission.", "doi": "10.3390/vaccines12040357", "pmid": "38675738", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11053591"}, {"db": "pii", "key": "vaccines12040357"}], "notes": [], "created": "2026-08-20T13:43:21.587Z", "modified": "2026-08-20T13:43:21.931Z"}]}